COVID 19

DXB: Making Strong Progress on “Main Bet,” Side Bet #2 Paused

Our 2021 Biotech Pick of the Year Dimerix (ASX:DXB) released its half year report last Thursday, updating investors on ethics approvals for its Phase III clinical trial for FSGS (a rare kidney disease) and closing in on important milestones for TWO of its Phase III COVID-19 studies.

DXB: Making Strong Progress on “Main Bet,” Side Bet #2 Paused

Our 2021 Biotech Pick of the Year Dimerix (ASX:DXB) released its half year report last Thursday, updating investors on ethics approvals for its Phase III clinical trial for FSGS (a rare kidney disease) and closing in on important milestones for TWO of its Phase III COVID-19 studies.

Earlier than Expected - DXB Gets First Regulatory Approval in Europe.

Dimerix (ASX:DXB) just delivered significant progress on its Phase III Clinical Trial for FSGS, with the first EU regulatory approval given for DXB’s kidney disease study in Denmark... earlier than expected.

DXB to run a Phase III COVID-19 Study in Australia

Dimerix (ASX:DXB) is moving fast with its Covid-19 trials, and today announced that this COVID-19 Phase III Study will expand to Australia.

DXB announces approval for Phase III COVID-19 trials

On Friday last week, DXB announced that the main drug regulator in India has recommended approval for DXB’s Phase III clinical trials on COVID-19 treatment, specifically for patients with respiratory complications intended for hospitalisation — its CLARITY 2.0 study.

DXB announces approval for Phase III COVID-19 trials in India

The main drug regulator in India has recommended approval for Dimerix Ltd's (ASX:DXB) Phase 3 clinical trials on its COVID-19 treatment for patients with respiratory complications.

Bod Australia outlines strong revenue growth

Medicinal cannabis, CBD and hemp healthcare products company, Bod Australia Limited (ASX: BDA) has provided its shareholders an update for the Q3FY2021 quarter, ended 31 March 2021.

Can BDA’s medical cannabis product treat long-COVID symptoms?

Bod Australia Limited (ASX: BDA) has entered into a collaboration agreement with the UK’s leading independent scientific body on drugs, Drug Science UK, which has the potential to unlock a large market opportunity for BDA in the treatment of long-term symptoms of COVID-19.

Australian stock market still the best performing in the world

The Australian market together with South Africa continue to be the best performing stocks markets in the world and have been for over 100 years.

Is Australia spending our grandchildren’s future?

In times of crisis, it seems that governments around the world are more than happy to continue to dish out ever increasing stimulus packages to solve the problem but are they just delaying the inevitable or are they spending our grandchildren’s future?

Achiko emerges as strong Covid-19 beneficiary

Achiko (SWX: ACHI), listed on the Switzerland Stock Exchange during the year, is transforming into a health technology company with the rapid development of Teman Sehat, an open source software product that provides an alternative way to manage Covid-19 testing, and ‘Gumnuts’, a potential rapid and low-cost virus detection technology.

Brexit and COVID impact markets while Airbnb gets set to list

Stocks were impacted last night as COVID-19 infections swept through the US again, putting the fear of further restrictions into investors.

Strong results show Alexium remains resilient in tough market

Despite retailers doing it tough throughout the COVID-19 global pandemic, there are certain suppliers that have managed to not only remain operational, but also thrive in a trying environment. Alexium International Group (ASX: AJX) is one.

The moral dilemma of sustainable packaging during a global pandemic

How could a virus press pause on global sustainability goals and instead make plastic fantastic again?

US markets frolic in the face of COVID, futures point to a tough start

To put things in perspective, the Dow Jones last traded around this level of February 21, a day on which the US recorded one new COVID-19 case.

Airbnb to IPO, Apple and Tesla investors get ready for stock split … and keep your eye on Calima Energy

Airbnb hasn’t been immune to the hospitality downturn, so it does seem a strange time to IPO. It would certainly rub the noses of the 25% of Airbnb staff that was laid off in May.

The times are a changin’, the markets are reacting, Amazon is hitting the high notes and … everyone loves Pizza

The S&P 500 regained all of the losses it suffered in March, when the pandemic hit. It is up 16.8% over the past 12 months. The stocks that make up the S&P 500 are mostly those which are trying to change the world in light of COVID-19.

Pay attention, ask the tough questions and plan for the future

Right now, it’s important to understand your level of exposure to Australian equities, particularly if the stock market crashes again, as some experts are predicting.

Are you a sophisticated investor?
Find out more
Please note: Raisebook is a related entity of S3 Consortium Pty Ltd as defined in Section 9 of the Corporations Act 2001.